Literature DB >> 21734783

miRNA studies in in vitro and in vivo activated hepatic stellate cells.

Gunter Maubach1, Michelle Chin Chia Lim, Jinmiao Chen, Henry Yang, Lang Zhuo.   

Abstract

AIM: To understand which and how different miRNAs are implicated in the process of hepatic stellate cell (HSC) activation.
METHODS: We used microarrays to examine the differential expression of miRNAs during in vitro activation of primary HSCs (pHSCs). The transcriptome changes upon stable transfection of rno-miR-146a into an HSC cell line were studied using cDNA microarrays. Selected differentially regulated miRNAs were investigated by quantitative real-time polymerase chain reaction during in vivo HSC activation. The effect of miRNA mimics and inhibitor on the in vitro activation of pHSCs was also evaluated.
RESULTS: We found that 16 miRNAs were upregulated and 26 were downregulated significantly in 10-d in vitro activated pHSCs in comparison to quiescent pHSCs. Overexpression of rno-miR-146a was characterized by marked upregulation of tissue inhibitor of metalloproteinase-3, which is implicated in the regulation of tumor necrosis factor-α activity. Differences in the regulation of selected miRNAs were observed comparing in vitro and in vivo HSC activation. Treatment with miR-26a and 29a mimics, and miR-214 inhibitor during in vitro activation of pHSCs induced significant downregulation of collagen type I transcription.
CONCLUSION: Our results emphasize the different regulation of miRNAs in in vitro and in vivo activated pHSCs. We also showed that miR-26a, 29a and 214 are involved in the regulation of collagen type I mRNA.

Entities:  

Keywords:  Hepatic stellate cells; Nuclear factor-κB; miR-146a; miRNA

Mesh:

Substances:

Year:  2011        PMID: 21734783      PMCID: PMC3122263          DOI: 10.3748/wjg.v17.i22.

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  49 in total

1.  Extracellular matrix gene expression increases preferentially in rat lipocytes and sinusoidal endothelial cells during hepatic fibrosis in vivo.

Authors:  J J Maher; R F McGuire
Journal:  J Clin Invest       Date:  1990-11       Impact factor: 14.808

2.  Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets.

Authors:  Benjamin P Lewis; Christopher B Burge; David P Bartel
Journal:  Cell       Date:  2005-01-14       Impact factor: 41.582

3.  Induction of cyclooxygenase-2 by the activated MEKK1 --> SEK1/MKK4 --> p38 mitogen-activated protein kinase pathway.

Authors:  Z Guan; S Y Buckman; A P Pentland; D J Templeton; A R Morrison
Journal:  J Biol Chem       Date:  1998-05-22       Impact factor: 5.157

4.  Inhibition of NFkappaB in activated rat hepatic stellate cells by proteasome inhibitors and an IkappaB super-repressor.

Authors:  C Hellerbrand; C Jobin; Y Iimuro; L Licato; R B Sartor; D A Brenner
Journal:  Hepatology       Date:  1998-05       Impact factor: 17.425

5.  Expression of microRNA-146 suppresses NF-kappaB activity with reduction of metastatic potential in breast cancer cells.

Authors:  D Bhaumik; G K Scott; S Schokrpur; C K Patil; J Campisi; C C Benz
Journal:  Oncogene       Date:  2008-05-26       Impact factor: 9.867

6.  Extracellular signal-regulated kinase activation differentially regulates platelet-derived growth factor's actions in hepatic stellate cells, and is induced by in vivo liver injury in the rat.

Authors:  F Marra; M C Arrighi; M Fazi; A Caligiuri; M Pinzani; R G Romanelli; E Efsen; G Laffi; P Gentilini
Journal:  Hepatology       Date:  1999-10       Impact factor: 17.425

7.  Role of NF-kappaB in the antiproliferative effect of endothelin-1 and tumor necrosis factor-alpha in human hepatic stellate cells. Involvement of cyclooxygenase-2.

Authors:  C Gallois; A Habib; J Tao; S Moulin; J Maclouf; A Mallat; S Lotersztajn
Journal:  J Biol Chem       Date:  1998-09-04       Impact factor: 5.157

8.  A p38 MAP kinase inhibitor regulates stability of interleukin-1-induced cyclooxygenase-2 mRNA.

Authors:  S H Ridley; J L Dean; S J Sarsfield; M Brook; A R Clark; J Saklatvala
Journal:  FEBS Lett       Date:  1998-11-13       Impact factor: 4.124

9.  Interleukin-1beta-induced cyclooxygenase-2 expression requires activation of both c-Jun NH2-terminal kinase and p38 MAPK signal pathways in rat renal mesangial cells.

Authors:  Z Guan; S Y Buckman; B W Miller; L D Springer; A R Morrison
Journal:  J Biol Chem       Date:  1998-10-30       Impact factor: 5.157

10.  The role of TGFbeta1 in initiating hepatic stellate cell activation in vivo.

Authors:  C Hellerbrand; B Stefanovic; F Giordano; E R Burchardt; D A Brenner
Journal:  J Hepatol       Date:  1999-01       Impact factor: 25.083

View more
  23 in total

Review 1.  Pivotal MicroRNAs in Melanoma: A Mini-Review.

Authors:  Zhenjun Deng; Jingang Hao; Dongyun Lei; Yongjing He; Lechun Lu; Li He
Journal:  Mol Diagn Ther       Date:  2016-10       Impact factor: 4.074

2.  Inhibition of miR-21 rescues liver regeneration after partial hepatectomy in ethanol-fed rats.

Authors:  Egle Juskeviciute; Rachael P Dippold; Anil N Antony; Aditi Swarup; Rajanikanth Vadigepalli; Jan B Hoek
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2016-09-15       Impact factor: 4.052

3.  GCA links TRAF6-ULK1-dependent autophagy activation in resistant chronic myeloid leukemia.

Authors:  Seung Hun Han; Sovannarith Korm; Ye Gi Han; Soo-Young Choi; Soo-Hyun Kim; Hee Jin Chung; Kibeom Park; Jae-Young Kim; Kyungjae Myung; Joo-Yong Lee; Hongtae Kim; Dong-Wook Kim
Journal:  Autophagy       Date:  2019-03-30       Impact factor: 16.016

4.  Mechanism and significance of changes in glutamate-cysteine ligase expression during hepatic fibrogenesis.

Authors:  Komal Ramani; Maria Lauda Tomasi; Heping Yang; Kwangsuk Ko; Shelly C Lu
Journal:  J Biol Chem       Date:  2012-08-31       Impact factor: 5.157

Review 5.  MicroRNAs as novel therapeutic targets to treat kidney injury and fibrosis.

Authors:  Ivan G Gomez; Naoki Nakagawa; Jeremy S Duffield
Journal:  Am J Physiol Renal Physiol       Date:  2016-02-24

6.  Protective effect of LNA-anti-miR-132 therapy on liver fibrosis in mice.

Authors:  Fatemeh Momen-Heravi; Donna Catalano; Austin Talis; Gyongyi Szabo; Shashi Bala
Journal:  Mol Ther Nucleic Acids       Date:  2021-05-14       Impact factor: 10.183

7.  The autoregulatory feedback loop of microRNA-21/programmed cell death protein 4/activation protein-1 (MiR-21/PDCD4/AP-1) as a driving force for hepatic fibrosis development.

Authors:  Zhengping Zhang; Yinhe Zha; Wei Hu; Zhen Huang; Zhongfei Gao; Yuhui Zang; Jiangning Chen; Lei Dong; Junfeng Zhang
Journal:  J Biol Chem       Date:  2013-11-06       Impact factor: 5.157

Review 8.  Dual role of microRNAs in NAFLD.

Authors:  Sara Ceccarelli; Nadia Panera; Daniela Gnani; Valerio Nobili
Journal:  Int J Mol Sci       Date:  2013-04-17       Impact factor: 5.923

9.  Overexpression of miR-483-5p/3p cooperate to inhibit mouse liver fibrosis by suppressing the TGF-β stimulated HSCs in transgenic mice.

Authors:  Fuyuan Li; Ning Ma; Ruiqi Zhao; Guodong Wu; Yanfen Zhang; Yu Qiao; Dong Han; Ya Xu; Ying Xiang; Bingzhu Yan; Jianfeng Jin; Guixiang Lv; Lei Wang; Changqing Xu; Xu Gao; Shanshun Luo
Journal:  J Cell Mol Med       Date:  2014-05-06       Impact factor: 5.310

Review 10.  The role of miRNAs in stress-responsive hepatic stellate cells during liver fibrosis.

Authors:  Joeri Lambrecht; Inge Mannaerts; Leo A van Grunsven
Journal:  Front Physiol       Date:  2015-07-28       Impact factor: 4.566

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.